AI as an always-available oncologist : a vision for AI-optimized cancer therapy based on real-time adaptive dosing at the patient level [Separata] /

This communication presents the long-term vision of AI-optimized cancer therapy based on automated adaptive dosing. The idea is to have an AI-controlled therapeutic system that administers microdoses from information obtained from low-power sensors, which could improve patient quality and survival....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mastroleo, Ignacio (Autor), Kalweit, Gabriel (Autor), García Valiña, Luis (Autor), Klett, Anusha (Autor), Boedecker, Joschka (Autor), Mertelsmann, Roland (Autor), Kalweit, Maria (Autor)
Autor Corporativo: FLACSO. Programa Argentina
Formato: Libro
Lenguaje:Inglés
Materias:
Acceso en línea:https://10.0.67.8/josha.11.1.975
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 02734nam a22004097a 4500
003 AR-BaFLA
005 20240904152323.0
008 240822t2024 ag d|||fs2||| 00| 0 eng d
037 |n Depósito reglamentario 
040 |a AR-BaFLA  |c AR-BaFLA  |b spa  |e rda 
041 0 |a eng 
100 1 |a Mastroleo, Ignacio  |9 19323  |e aut. 
110 2 |a FLACSO. Programa Argentina  |9 110 
245 1 0 |a AI as an always-available oncologist :   |b a vision for AI-optimized cancer therapy based on real-time adaptive dosing at the patient level [Separata] /   |c Gabriel Kalweit, Luis García Valiña, Ignacio Mastroleo, Anusha Klett, Joschka Boedecker, Roland Mertelsmann, Maria Kalweit  |h DIG 
300 |a 11 p. 
336 |2 rdacontent  |a Texto  |b txt 
337 |2 rdamedia  |a computadora  |b c 
338 |2 rdacarrier  |a Recurso el línea  |b cr 
504 |a incl. ref. 
520 |a This communication presents the long-term vision of AI-optimized cancer therapy based on automated adaptive dosing. The idea is to have an AI-controlled therapeutic system that administers microdoses from information obtained from low-power sensors, which could improve patient quality and survival. While this idea has not been implemented for cancer yet, there are similar health interventions in cancer (not using AI) and in diabetes (using AI) that serve as precedents. However, there are still major challenges to tackle, such as identifying relevant, measurable, and reasonably costly tumor markers and dealing with the enormous combinatorial potential for a rapid and effective response in individual cases. The paper proposes a dual process to address these challenges, involving collecting initial findings in vitro and investigating tumor markers for their transferability to in vivo systems. If successful, this intervention strategy could have vast implications for the treatment of cancer, the second leading cause of death in the world. It is important to consider ethical and regulatory considerations in the development of this strategy. 
650 4 |a  INTELIGENCIA ARTIFICIAL  |9 6857 
650 4 |a TRATAMIENTO ONCOLOGICO  |9 11827 
650 4 |a CANCER  |9 5723 
650 4 |a MEDICAMENTOS  |9 924 
650 4 |a RELACION MEDICO PACIENTE  |9 10122 
650 4 |a SERVICIOS DE SALUD  |9 2238 
690 |a BIOETICA 
700 1 |a Kalweit, Gabriel  |9 39009  |e aut. 
700 1 |a García Valiña, Luis  |9 39010  |e aut. 
700 1 |a Klett, Anusha  |9 39011  |e aut. 
700 1 |a  Boedecker, Joschka  |9 39012  |e aut. 
700 1 |a Mertelsmann, Roland  |9 33578  |e aut. 
700 1 |a Kalweit, Maria   |9 39013  |e aut. 
773 |d Freiburg : JOSHA, 2024  |t Journal of science humanities and arts  |g Vol. 11, no 2  |x 2364-0626 
856 |u https://10.0.67.8/josha.11.1.975 
942 |c ART 
999 |c 51566  |d 51566